Ramya Devanand | Head of BD Search and Evaluation
Norgine

Search and evaluation leader with 20+ years in commercial and business development roles across rare disease, specialty pharma and biotech investing decisions. Recent deal experience includes closing four transactions in 2024–25: three European in-licensing deals representing over €1 billion in aggregate potential consideration, plus royalties and cost-sharing, and one M&A transaction - all focussed on rare diseases. Combines disciplined asset selection, commercial diligence, valuation, portfolio strategy and board-level investment cases across Big Pharma, growth-stage biotech and private equity-backed healthcare. Interested in speaking with companies looking for an experienced partner for their late stage (Phase 3+), nearly commercial or commercialised speciality / hospital / rare disease drugs in Europe. Please get in touch at rdevanand@norgine.com.